Savara Inc stock hits 52-week low at $4.05 By Investing.com
Savara Inc. stock recently hit a 52-week low of $4.13, trading at $4.24, despite a strong 12.28% return over the past week. Analysts do not foresee profitability this year, and the stock may be overvalued relative to its Fair Value according to InvestingPro. However, there's optimism surrounding its drug Molbreevi, with H.C. Wainwright and Citizens reiterating "buy" and "Market Outperform" ratings respectively, both with a $10.00 price target, ahead of its PDUFA target action date of November 22, 2026.
FDA delays decision on Savara’s autoimmune PAP treatment
The FDA has delayed its decision on Savara Inc.'s Biologics License Application for molgramostim inhalation solution, a treatment for autoimmune pulmonary alveolar proteinosis (PAP). The agency has not provided a new action date, with the review of the application still ongoing. Savara's molgramostim is an investigational drug designed to address the abnormal surfactant buildup in the lungs characteristic of autoimmune PAP.
Why is Savara stock plunging today?
Savara stock is plunging today after the U.S. FDA announced it would not meet the November 22, 2026, target action date for the molgramostim inhalation solution Biologics License Application, with no revised approval timeline provided. This deferral has caused the stock to unwind recent gains, trading near its 52-week low, especially amid a broader market downturn. Despite analyst buy ratings, the regulatory uncertainty and market risk-off sentiment are negatively impacting investor confidence.
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
Savara Inc. announced that the FDA will not meet the PDUFA target action date of November 22, 2026, for its molgramostim inhalation solution Biologics License Application (BLA) for autoimmune PAP. The FDA's review of the BLA is ongoing, and no revised action date has been provided. Savara's CEO, Matt Pauls, expressed appreciation for the FDA's efforts and looks forward to working with the agency to complete the review.
A holder reports over 11 million Savara (SVRA) shares in a passive stake.
Polar Capital Holdings Plc and Polar Capital LLP have each reported a 5.58% passive stake in Savara Inc. (SVRA), beneficially owning 11,456,114 common shares as of September 30, 2026. This disclosure was made via a Schedule 13G SEC filing, indicating that they each hold sole voting and dispositive power over these shares. The percentage is based on 205,460,015 Savara shares outstanding as reported in the issuer’s Form 10-Q.
FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
The FDA is poised to announce decisions on three applications this week, including Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy (DMD) and Savara's Molbreevi for autoimmune pulmonary alveolar proteinosis. Capricor's Deramiocel faces a critical decision after a previous rejection and an unfavorable advisory panel vote, while analysts at JPMorgan see blockbuster potential for Savara's Molbreevi ahead of its November 22 verdict. Additionally, Beren Therapeutics awaits a decision on Adrabetadex for infantile-onset Niemann-Pick disease type C.
HC Wainwright & Co. assumes coverage of Savara at Buy, sets price target at $10
HC Wainwright & Co. has initiated coverage of Savara (SVRA) with a "Buy" rating and a price target of $10. This target suggests a potential upside of 100.4% from the stock's closing price of $4.99 on November 11. Investors can find more detailed analyst data and ratings for Savara on the Forecasts tab and track all recommendations in the News Flow section.
Savara Reports Molgramostim Benefits in Exploratory Lung Study
Savara Inc. reported that its experimental drug molgramostim showed improvements in pulmonary gas transfer and lung imaging for patients with autoimmune pulmonary alveolar proteinosis (aPAP) in a retrospective analysis. The findings, presented at CHEST 2026, suggest potential benefits for aPAP patients with relatively normal lung diffusion capacity, though the small subgroup analysis (11 patients) is considered exploratory and not definitive proof of efficacy. The company continues to develop molgramostim for this rare respiratory disease.
Savara Inc (YB4P.MU) Seasonal Returns Chart - Yahoo Finance
The article displays a seasonal returns chart for Savara Inc (YB4P.MU) on Yahoo Finance. It provides historical seasonality data showing the average monthly price return from 2016 to 2026. The current quote for Savara Inc is 4.4220 EUR, with no change as of 8:01:01 a.m. GMT+1.
Molgramostim Trial Update Might Change The Case For Investing In Savara (SVRA)
Savara Inc. recently presented exploratory post-hoc data from its IMPALA trial at CHEST 2026, suggesting molgramostim treatment may offer descriptive improvements for aPAP patients with mild impairment. While these findings hint at a broader treatable group, the small sample size means the investment narrative for Savara, a pre-revenue company focused on a single asset, remains largely tied to IMPALA 2 progress, regulatory interactions, and its cash runway. Investors should consider the high execution risk given the company's current valuation without revenue.
SVRA Q3'26 Earnings: revenue estimate is 0 USD
Savara, Inc. (SVRA) is scheduled to release its Q3'26 earnings on November 05, with an expected revenue estimate of 0 USD and an anticipated EPS of (0.16) USD. The earnings are projected to be disclosed at 7:00 AM ET (12:00 PM UTC). More details can be found on the SVRA Financials page.
Molgramostim Trial Update Might Change The Case For Investing In Savara (SVRA)
Savara Inc. presented new exploratory data from a post-hoc IMPALA trial analysis for molgramostim in aPAP patients, suggesting descriptive improvements in those with mildly impaired diffusion capacity. While the small patient subset limits immediate impact, these findings refine Savara's investment thesis, which remains heavily reliant on molgramostim's execution, regulatory progress, and financial stability. Investors should consider the execution risk given the company's pre-revenue status and high valuation compared to peers.
Savara stock: Savara presents CHEST data before FDA decision for Savara stock
Savara (SVRA) presented new molgramostim data at the CHEST 2026 meeting on October 21, 2026, ahead of a critical FDA decision on MOLBREEVI for autoimmune pulmonary alveolar proteinosis. The FDA extended the review period by three months, with a decision now expected on November 22, 2026. Subgroup analysis from the IMPALA trial showed improvement in oxygen gradient for molgramostim patients, although the findings are exploratory due to a small sample size.
Savara, Inc. Estimates – NASDAQ:SVRA
This page on TradingView provides financial estimates and data for Savara, Inc. (NASDAQ: SVRA). It allows users to explore reported financial data and analyst estimates across various statements and metrics, compare actual results with estimates, and visualize trends over time. The content focuses on the company's financial overview, statements, statistics, estimates, dividends, and earnings.
Savara presents CHEST data before the FDA decision for Savara stock
Savara presented molgramostim data at CHEST 2026 and its stock is trading at EUR 4.17 ahead of the FDA's November 22, 2026 decision. The company reported a Q2 2026 net loss of USD 40.2 million but maintains USD 173.0 million in cash to support the launch. Savara Inc. is focused on its lead respiratory program with an approaching regulatory decision.
Savara schedules CHEST 2026 presentations for Savara stock
Savara is preparing for key presentations at CHEST 2026 regarding its molgramostim data, including an oral presentation on long-term efficacy and safety, and a poster on treatment effects. These events precede an important FDA decision on MOLBREEVI on November 22, 2026, and the release of Q3 2026 results around November 11, 2026. The company's stock valuation is closely tied to these upcoming clinical and financial milestones.
Savara presents CHEST 2026 data: Savara stock is valued at USD 978.0 million
Savara Inc. is set to present IMPALA trial data at CHEST 2026 from October 18-21, 2026, with an emphasis on the long-term efficacy and safety of molgramostim for autoimmune pulmonary alveolar proteinosis. The company's stock was trading at EUR 4.28 on October 15, 2026, with a market capitalization of USD 978.0 million as of October 14, 2026. Analysts have an average 12-month target of USD 10.25, with upcoming catalysts including the CHEST presentations and third-quarter results expected on November 11, 2026.
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
Savara Inc. announced that CHEST 2026 will feature an encore oral presentation and a poster on molgramostim data for autoimmune pulmonary alveolar proteinosis, focusing on long-term efficacy and safety. While this reinforces the drug's potential, especially for milder cases, it doesn't change the regulatory timetable for MOLBREEVI. The article suggests that regulatory outcomes, commercialization, and potential shareholder dilution remain key risks for Savara's investment narrative.
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Savara Inc. announced that it will present new analysis from the Phase 2/3 IMPALA clinical trial and deliver an encore presentation of long-term data from the Phase 3 IMPALA-2 clinical trial on molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) at CHEST 2026. The company will also host a learning theatre session on aPAP, featuring a key opinion leader and patient community members. These presentations highlight Savara's ongoing commitment to advancing treatments for rare respiratory diseases.
Molgramostim Data Preview Could Be A Big Test For Savara Stock (SVRA)
Savara Inc. is facing a crucial period as upcoming data from its molgramostim IMPALA-2 trial, to be presented at CHEST 2026, will heavily influence its investment narrative. The company, focused on rare respiratory diseases, has no current revenue and a significant market cap relying on the future success of molgramostim. Investors are keenly watching for clean Phase 3 data and regulatory progress, as recent stock performance has been mixed, reflecting underlying execution and capital risks.
Molgramostim Data Preview Could Be A Big Test For Savara Stock (SVRA)
Savara Inc. announced that CHEST 2026 accepted an encore oral presentation from its Phase 3 IMPALA-2 trial and a poster from its Phase 2/3 IMPALA study, both focused on molgramostim for autoimmune pulmonary alveolar proteinosis. The company's investment narrative is heavily reliant on molgramostim, with upcoming data from the IMPALA-2 trial expected to be a significant test. Savara, a clinical-stage biotech with no current revenue, faces execution risk due to a single lead asset and capital needs.
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Savara Inc. announced that it will present new analyses from its IMPALA clinical trials and long-term data on molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) at the CHEST 2026 conference. The presentations will include an encore oral presentation on the IMPALA-2 trial's long-term efficacy and safety, and a poster on molgramostim's effects in aPAP patients with mild diffusion impairment. Savara will also host a Learning Theatre session to discuss aPAP with a key opinion leader and patients.
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Savara Inc. announced it will present new analysis from its IMPALA clinical trial and deliver an encore presentation of long-term data on molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) at CHEST 2026. The company will host an oral presentation on the IMPALA-2 trial results and a poster presentation on the IMPALA trial, both focusing on molgramostim's efficacy and safety. Additionally, Savara will host a Learning Theatre session to enhance understanding of aPAP with a key opinion leader and patients.
Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
JPMorgan initiated coverage on Savara (SVRA) with an Overweight rating and a $12 price target, despite the stock losing 30% since December 2025. The firm's positive outlook is based on the potential FDA approval of Savara's only drug, Molbreevi, on November 22, which could drive a significant re-rating of the stock. While the target aligns with the Street's consensus, the implied valuation multiple is high and largely contingent on a successful FDA decision.
JPMorgan starts Savara coverage with USD 12 target for Savara stock
JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and a USD 12.00 price target on October 7, 2026. This comes as Savara reported a Q2 2026 loss of USD 0.16 per share, slightly higher than the USD 0.14 expected. Key upcoming dates include the FDA decision for Molbreevi on November 22, 2026, and the next earnings release on November 5, 2026.
JPMorgan Initiates Savara at Overweight With $12 Price Target
JPMorgan has initiated coverage on Savara (SVRA) with an "Overweight" rating and set a price target of $12. This rating is higher than the average analyst rating of "buy" and mean price target of $11.06 for Savara. The article, however, notes that full details are only available to premium subscribers.
Savara stock gets USD 12 JPMorgan target before FDA date
JPMorgan initiated coverage on Savara (SVRA) with an Overweight rating and a $12 price target, despite the stock's recent quarterly loss. The company's lead candidate, molgramostim, awaits an FDA decision on November 22, 2026, which is seen as the next major catalyst for its valuation. While the average analyst target is higher, the stock traded at $4.9850 on October 7, 2026, after a significant intraday gain.
Savara stock fell 4.66 percent ahead of the November FDA decision
Savara stock (SVRA) dropped 4.66% as investors await an FDA decision on Molbreevi for autoimmune pulmonary alveolar proteinosis, scheduled for November 22, 2026. Despite a Q2 adjusted EPS miss, analysts maintain a "Moderate Buy" consensus with an average target of USD 10.00, significantly above the current price, though one firm recently downgraded the stock to "Sell." The upcoming FDA decision is seen as central to the investment case for Savara.
Savara stock sits 26.39 percent below its 52-week high
Savara stock (SVRA) is trading at EUR 4.59, 26.39 percent below its 52-week high of USD 7.01. The company reported a second-quarter loss of USD 0.16 per share, missing estimates. Analysts have an average 12-month price target of USD 10.00 for the stock, and the next earnings report is scheduled for November 5, 2026.
Savara Inc CCO Braden Parker Withholds 29,323 Shares for RSU Tax Settlement
Savara Inc.'s Chief Commercial Officer, Braden C. Parker, withheld 29,323 shares of common stock on September 24, 2026, to cover tax obligations from the vesting of restricted stock units. These shares were valued at $5.07 each. Following this transaction, Parker directly holds 75,677 shares of Savara common stock.
Form 4 Savara Inc For: 25 September By Investing.com
This article announces the filing of Form 4 by Savara Inc. on September 25, reporting insider transactions. The brief piece provides the company name and filing date, without offering further details on the transactions themselves. It is published by Investing.com, a financial markets news platform.
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?
Savara Inc. (SVRA) is awaiting an FDA decision on its drug Molbreevi for autoimmune pulmonary alveolar proteinosis (aPAP), expected by November 22, 2026. If approved, Molbreevi would be the first specific treatment for aPAP, addressing a significant unmet medical need in this rare lung disease. The full article content is behind a paywall for RTT Biotech Investor and Intelligent Investor subscribers.
Savara Inc (YB4P.DU) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed information for Savara Inc (YB4P.DU), including its stock price, news, quotes, and historical data. The stock is listed on the Dusseldorf exchange and showed a 3.11% decrease as of the reported time. The page also offers related tickers and general market data.
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)?
This article analyzes when Savara Inc. (NASDAQ:SVRA) is expected to become profitable based on analyst forecasts. It examines the company's current financial position, revenue growth, and expenses to project the timeline for achieving positive net income. The analysis provides insights into the key factors influencing Savara's path to profitability.
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative
Savara Inc. announced that long-term Phase 3 IMPALA-2 trial data for its molgramostim therapy in autoimmune pulmonary alveolar proteinosis (aPAP) has been accepted for presentation at the ERS Congress in September 2026. This data focuses on sustained efficacy, safety, and biomarker changes, reinforcing the clinical story for a drug targeting a rare lung disease with no approved treatments. While these presentations will support the drug's potential, Savara faces financial challenges including rising losses and dilution risk, with the upcoming FDA decision in November 2026 being a key near-term catalyst.
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)?
Savara Inc. announced that its Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) will be presented at the ERS Congress in Barcelona in September 2026, showcasing long-term efficacy, safety, and biomarker findings. While this reinforces the scientific story of molgramostim, the core investment narrative for Savara hinges on the upcoming FDA approval in November 2026, with the company facing risks like regulatory outcomes, lack of revenue, and widening losses. Investors should consider these factors and other valuation perspectives beyond the ERS data.
Savara Loss Widens as Lung Drug Nears FDA Decision
Savara Inc. reported a wider second-quarter loss of $40.2 million, or 16 cents per share, as it expanded its commercial operations in anticipation of a November 22 FDA decision on its rare-disease drug, MOLBREEVI. The company's general and administrative expenses increased significantly due to higher personnel costs and infrastructure building for the potential U.S. market launch. Savara ended the quarter with strong cash reserves and expects decisions on MOLBREEVI from European and U.K. regulators in late 2026 and early 2027, respectively.
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Inc. will present results from its Phase 3 IMPALA-2 clinical trial for molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis (aPAP) at the European Respiratory Society (ERS) Congress in September 2026. The presentations will cover long-term efficacy, safety, and improvements in lung function, exercise capacity, and quality of life for patients. The company will also host an industry mini-symposium on aPAP.
Savara presents molgramostim data at ERS Congress in September
Savara Inc. (NASDAQ:SVRA) announced that data from its Phase 3 IMPALA-2 clinical trial for molgramostim will be presented at the ERS Congress in Barcelona from September 5-9, 2026. These presentations will include an oral presentation on long-term efficacy and safety, and two poster presentations on exercise capacity improvements and biomarker levels. Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor in development for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved pharmacologic treatments.
Why Savara (SVRA) Is Getting Attention Today
Savara (SVRA) is attracting attention after reporting a net loss of US$40.23 million and filing a US$108.297 million shelf registration, despite its share price showing a 76.9% one-year return. The company's stock trades at a high price-to-book ratio of 9.9x, significantly above industry averages, suggesting investors are paying a premium based on expectations for its rare respiratory disease pipeline, specifically the Phase 3 molgramostim program. However, ongoing losses and the new shelf registration could temper investor sentiment.
Savara Announces New Employment Inducement Grant - August 20, 2026
Savara Inc. announced inducement grants to eight new employees, consisting of options to purchase 74,500 shares and restricted stock units (RSUs) covering 64,500 shares. These awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, in accordance with NASDAQ Listing Rules, to attract and retain talent. The options have a 10-year term and vest quarterly, while RSUs vest fully on the two-year anniversary of employment, all subject to continued employment.
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11
This article provides an overview of recent analyst ratings for Savara (SVRA.US), highlighting that analysts forecast a price target between $9 and $11. It compiles a consensus based on ratings from Wall Street analysts, offering investors insight into expert opinions on the stock's potential performance.
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA
Walleye Capital LLC has initiated a new position in Savara Inc. (NASDAQ:SVRA) by acquiring 248,720 shares valued at approximately $1.53 million during the second quarter. Despite mixed analyst sentiment, with a "Moderate Buy" consensus but recent downgrades, institutional investors collectively hold 87.93% of the company. Savara reported a quarterly loss exceeding expectations, and analysts project continued losses for the foreseeable future.
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Savara (NASDAQ:SVRA) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Moderate Buy" with a $10.14 price target. The company recently reported a quarterly loss of $0.16 per share, missing expectations, and analysts have lowered earnings forecasts through 2030, projecting continued losses before eventual profitability. Institutional investors hold a significant 87.93% stake in the clinical-stage biopharmaceutical company.
HC Wainwright Brokers Lower Earnings Estimates for Savara
HC Wainwright has lowered its Q3 2026 earnings per share estimate for Savara to a loss of $0.16, down from $0.15, and projects full-year losses through 2028. This adjustment follows Savara's Q2 earnings report, where the company missed consensus estimates with a loss of $0.16 per share. Despite these revised estimates, analysts maintain a "Moderate Buy" rating for Savara with an average price target of $10.14, while institutional investors hold a significant 87.93% stake in the clinical-stage biotech firm.
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for potential share dilution, primarily for an ESOP-related offering. Despite this, the company's investment narrative remains closely tied to the upcoming regulatory decisions for its lead therapy, MOLBREEVI, in the U.S. and Europe, which are expected in late 2026 and early 2027. Investors are advised to weigh the dilution risk against the potential impact of these regulatory outcomes.
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings
HC Wainwright has revised its FY2029 EPS forecast for Savara Inc. (NASDAQ:SVRA) down to $0.09 from $0.11, while projecting FY2030 EPS at $0.37. This revision is still notably above the current full-year consensus estimate of a $0.57 loss per share. Savara recently reported a quarterly loss of $0.16 per share, missing analyst consensus, but its shares rose 2.3% to $5.70.
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary
Savara Inc reported a net loss of $(40.2M) and an EPS of $(0.16) for Q2 2026, widening its loss compared to the previous year. As a pre-revenue biopharma company, its financial highlights showed increased losses while business highlights focused on regulatory milestones, clinical progress for MOLBREEVI, and commercial readiness for potential product launches in key markets. The company also continues to invest in R&D and manufacturing to support future supply and regulatory approval.
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for common shares, primarily for an ESOP-related offering. Despite the financial losses and potential dilution, the company's investment narrative remains tied to upcoming regulatory decisions for its lead therapy, MOLBREEVI, in the U.S. and Europe, which are expected in late 2026 and early 2027. Investors are weighing the dilution risk against the potential upside from these regulatory outcomes.
SAVARA Q2 EPS USD -0.16
The article reports that Savara (SVRA) announced its Q2 Earnings Per Share (EPS) as USD -0.16. This financial figure indicates the company's profitability during the second quarter.